Section Arrow
SGMT.NASDAQ
- Sagimet Biosciences
Quotes are at least 15-min delayed:2026/03/05 06:01 EST
Pre Market
Last
 5.8
+0.043 (+0.75%)
Bid
4.8
Ask
6.5
High 5.8 
Low 5.76 
Volume 196 
Regular Hours (Closed)
Last
 5.76
+0.15 (+2.67%)
Day High 
5.86 
Prev. Close
5.61 
1-M High
6.67 
Volume 
220.96K 
Bid
4.8
Ask
6.5
Day Low
5.5401 
Open
5.65 
1-M Low
4.92 
Market Cap 
182.45M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 5.62 
20-SMA 5.58 
50-SMA 5.83 
52-W High 11.41 
52-W Low 1.73 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.78/-1.81
Enterprise Value
182.45M
Balance Sheet
Book Value Per Share
3.67
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
KLTOKlotho Neurosciences Inc0.4126-0.1304-24.01%-- 
Pre Market 0.4119 -0.0007 -0.17%
IBOImpact BioMedical Inc.0.4133+0.0033+0.80%-- 
Pre Market 0.7488 +0.3355 +81.18%
CANFCan-Fite Biopharma Ltd6.02+1.02+20.40%-- 
Pre Market 5.43 -0.59 -9.80%
IBRXImmunityBio9-1.005-10.04%-- 
Pre Market 8.98 -0.02 -0.22%
QNCXQuince Therapeutics0.104+0.007+7.22%-- 
Pre Market 0.1206 +0.0166 +15.96%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.